Ligand-induced genetic degradation as a tool for target validation
- 1 April 2019
- journal article
- review article
- Published by Elsevier in Drug Discovery Today: Technologies
- Vol. 31, 91-98
Abstract
No abstract availableKeywords
Funding Information
- JSPS KAKENHI (18H02170, 18H04719)
- CANON Foundation
- Asahi Glass Foundation
- Takeda Science Foundation
This publication has 52 references indexed in Scilit:
- Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15Science, 2017
- Induced protein degradation: an emerging drug discovery paradigmNature Reviews Drug Discovery, 2016
- Phthalimide conjugation as a strategy for in vivo target protein degradationScience, 2015
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros ProteinsScience, 2014
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma CellsScience, 2014
- Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBNBritish Journal of Haematology, 2013
- Jostling for Position: Optimizing Linker Location in the Design of Estrogen Receptor‐Targeting PROTACsChemMedChem, 2010
- Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding ProteinsJournal of the American Chemical Society, 2010
- siRNA applications in nanomedicineWIREs Nanomedicine and Nanobiotechnology, 2010
- Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradationProceedings of the National Academy of Sciences, 2001